Article Information
History
- October 1, 2021.
Article Versions
- You are currently viewing Version 1 of this article (October 1, 2021 - 18:47).
- Version 2 (October 6, 2021 - 10:13).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- E. Daoud1,2,*,
- A. S. Hamy-Petit1,3,
- E. Dumas1,4,
- L. Delrieu1,
- B. Grandal Rejo1,5,
- C. Le Bihan-Benjamin6,
- S. Houzard6,
- P. J. Bousquet7,10,
- A. M. Savoye8,
- C. Jouannaud8,
- J. Hotton9,
- C. A. Azencott4,
- M. Lelarge2 and
- F. Reyal1,5,9
- 1Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris, 75005 Paris, France
- 2INRIA, DI/ENS, PSL Research University, Paris, France
- 3Department of Medical Oncology, Institut Curie, Paris, France
- 4Mines ParisTech, PSL Research University, CBIO-Centre for Computational Biology, Paris, France
- 5Department of Surgery, Institut Curie, Paris, France
- 6Health Data and Assessment Department, Survey Data Science and Assessment Division, National Cancer Institute, 52 avenue André Morizet 92100 Boulogne-Billancourt, France
- 7Survey Data Science and Assessment Division, National Cancer Institute, 52 avenue André Morizet 92100 Boulogne-Billancourt, France
- 8Department of Medical Oncology, Institut Jean Godinot, Reims, France
- 9Department of Surgery, Institut Jean Godinot, Reims, France
- 10Aix Marseille Univ, Inserm, IRD, SESSTIM, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
- ↵*Correspondence to: Eric Daoud, Residual Tumor & Response to Treatment Laboratory, Institut Curie, 26 rue d’Ulm, 75011 Paris, France. E-mail: eric.daoud{at}curie.fr.
Posted October 01, 2021.
